There’s One More Step to

Put a Checkmark Next to Biomarker Testing

If you’ve been diagnosed with early-stage non-small cell lung cancer (NSCLC),* you probably already know the specific stage of your cancer and other details too.

But did you know that there is an additional test for EGFR mutations—whether you’ve already had surgery or are going to—that can help you and your doctor get a more complete diagnosis for a deeper understanding of your specific type of cancer?

*Stages IB-IIIA.


Doctor and patientLungs icon

Illustrated icon of a checkmarkIllustrated icon of a checkmark


Discuss Biomarker Testing With Your Cancer Care Team

Doctor and patientLungs icon

Biomarker testing for EGFR mutations can be done on the lung cancer tissue that is removed from your body during surgery.

Testing your tissue can reveal if your cancer is positive for EGFR mutations, which can help your doctors determine the most appropriate treatment plan for you after surgery. So make sure to talk about this important next step with your team.

Doctor on a tabletStethoscope icon

violet border

Test border image

Illustrated icon of a checkmarkIllustrated icon of a checkmark


Learn More About Your Cancer With Biomarker Testing

Doctor testingBiomarker testing icon

Certain biomarkers—such as EGFR mutations— can be the “drivers” that cause NSCLC to grow and spread. But you may not learn about biomarkers from an initial diagnosis. It’s important to get biomarker testing to help inform your treatment plan. It helps your care team understand what treatment options may be best to help keep your cancer from coming back after surgery.

When can you get biomarker testing?

Testing for EGFR mutations may be done after surgery, and it can be considered if you are a candidate for tumor removal. It can also be done whether or not you are undergoing chemotherapy or have already undergone chemotherapy. If you’ve had surgery but are not sure if you’ve had biomarker testing, be sure to ask your care team. Tissue that was removed may still be available for testing. Biomarker testing should not involve any further invasive treatments.

Why is Biomarker Testing for EGFR Mutations So Important?

NSCLC may come back following surgery

Epidermal Growth Factor Receptor (EGFR) is a common biomarker in NSCLC. Normally, EGFR helps healthy cells grow and divide. However, EGFR mutations can cause cancer cells to grow and spread—even after surgery. That’s why it’s so important to find out if your cancer tests positive for EGFR mutations.

Biomarker testing for EGFR mutations can help determine the best treatment options to help keep non-small cell lung cancer from coming back, even after surgery.

Prevalence of EGFR Mutations in Adenocarcinoma*

*Based on data from 3 references: Sholl et al (2015) analyzed 1007 samples from patients diagnosed with lung adenocarcinoma1; Jones et al (2019) analyzed genomic differences across pathologic stages in an unnamed number of patients with lung adenocarcinoma2; and D’Angelo et al (2012) analyzed tumors from 1118 patients with stage I-III surgically resected lung adenocarcinomas.3

Illustrated icon of a checkmarkIllustrated icon of a checkmark


Determine Your Treatment Plan After Surgery

After biomarker testing for EGFR mutations, your care team will review your test results with you. They may suggest “adjuvant treatment,” which is treatment following surgery to help keep your non-small cell lung cancer from coming back.

Doctor sharing with patientCancer treatment icon

Treatments after surgery may include:

Targeted Therapy:

Oral option for patients who test positive for certain biomarkers.


Drugs that treat cancer that can be administered by different ways, but more commonly through IV into your vein. It can be given in a doctor's office, hospital, infusion clinic, or at home.


A kind of treatment that uses high energy rays or waves.

The right treatment plan after surgery may help keep your cancer from coming back.
So review your biomarker testing results and make a plan with your doctors and care team.

Doctor sharing with patientCancer treatment icon




Talk to your cancer care team about biomarker testing before determining which treatment options may be right for you. Your cancer care team should always include an oncologist.




The tissue that was removed during surgery will be tested for EGFR mutations.




Biomarker testing can reveal specific information about your non-small cell lung cancer, which can help your care team determine which treatment options may help keep cancer from coming back after surgery.




1 Sholl LM, Aisner DL, Varella-Garcia M, et al; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015;10(5):768-777. doi:10.1097/JTO.0000000000000516

2 Jones DR. Introducing tumor genomics to predict recurrence following complete resection of lung adenocarcinoma. Presented at: 2019 American Association for Thoracic Surgery; May 4-7, 2019; Toronto, Canada.

3 D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7(12):1815-1822. doi:10.1097/JTO.0b013e31826bb7b2

The information on this Web site is provided by AstraZeneca for educational purposes only and should not take the place of talking with your doctor or health care professional. It should not be used for diagnosing or treating a health problem or disease. If you have any questions about your medical condition, talk to your doctor or pharmacist.

This information is intended for US consumers only.